← board
PTPI
distress 5/10 · elevated risk$0.000%today-87% from 52w high
Revenue
pre-revenue
Liquidity
$4M
Runway
0.7 yrs
Shares 1y
0%
Price & events
-50.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
-33.3%
1M
-50.0%
3M
-50.0%
6M
-86.7%
1Y
-100.0%
2Y
-100.0%
5Y
-100.0%
All
Overview
- Market Cap
- $169.49K
- Volume
- 1.21K
- 52 Week Range
- $0.00 – $0.03
- Total Shares
- 42.37M
- Float Shares
- 28.93M
- Short %
- 25.07%
- % Held by Insiders
- 24.08%
- % Held by Institutions
- 10.24%
- RVOL
- 0.01x
- Beta
- 1.87
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 2
- 2025-06-16withdrawalAssignment of all assets of subsidiaries (Metuchen, Timm Medical, Pos-T-Vac) for benefit of creditors; subsidiaries cease operations.SEC 8-K
- 2025-03-31withdrawalStendra · Termination of Vivus License Agreement, ceasing development, manufacturing, and commercialization of Stendra in licensed territory.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.